• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Clover Inc. To Go Public Through Merger With FoxWayne Enterprises Acquisition Corp.

    9/20/22 8:14:04 AM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FOXW alert in real time by email

    New entity poised to accelerate the development of Clover's next generation platform for live streaming with a suite of new product introductions.

    Clover has a growing user base of over 9 million with almost 90% of users between 18-39 years old.  Clover is targeting a launch of VR ('Virtual Reality') Dating and VR Live Streaming in Q4 2023.

    NEW YORK, Sept. 20, 2022 /PRNewswire/ -- Clover Inc. ("Clover" or the "Company"), a highly rated live streaming company focused on Gen Z and Millennial audiences and creators, and FoxWayne Enterprises Acquisition Corp. (NASDAQ: FOXW, FOXWW) ("FoxWayne"), a special purpose acquisition company ("SPAC"), today announced they have entered into a definitive business combination agreement. Upon closing of the transaction, which is currently anticipated to occur in the first quarter of 2023, the combined company will be named "Clover Media Inc." and will be led by Isaac Raichyk, Chief Executive Officer of Clover, and the current management team. The combined company's common stock is expected to continue to be listed on the Nasdaq Capital Market.

    (PRNewsfoto/FoxWayne Enterprises Acquisition Corp)

    "We are deeply committed to advancing Clover's exciting live streaming platform. This transaction is expected to accelerate the development of our lead offerings for over 9 million and growing users," said Mr. Raichyk.

    Robb Knie, chief executive officer of FoxWayne, added, "We see immense opportunities in Clover's approach to delivering both dating subscriptions and the live streaming dating and subscription models for creators of live content."

    Summary of the Transaction

    As part of the transaction, FoxWayne will be issuing 15.745 million shares of its common stock, which represents consideration of approximately $157.45 million. Current Clover stockholders will convert 100% of their existing equity interests into common stock of the combined company and will own a majority of the outstanding shares of the combined company post-closing. Assuming no redemptions of FoxWayne shares, the combined company's cash resources are expected to be comprised of  approximately $13.7 million in cash proceeds currently in trust, along with the existing cash resources of Clover at closing.

    The boards of directors of both Clover and FoxWayne have unanimously approved the proposed transaction. The transaction is subject to, among other things, the approval of the stockholders of both Clover and FoxWayne and satisfaction or waiver of the conditions stated in the definitive business combination agreement.

    The description of the business combination contained herein is only a high-level summary. Additional information about the proposed transaction, including a copy of the business combination agreement, will be provided in a Current Report on Form 8-K to be filed by FoxWayne with the Securities and Exchange Commission ("SEC") and will be available at the SEC's website at www.sec.gov. In addition, Fox Wayne intends to file a registration statement on Form S-4 with the SEC, which will include a proxy statement/prospectus, and will file other documents regarding the proposed transaction with the SEC.

    Get the next $FOXW alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FOXW

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FOXW
    SEC Filings

    View All

    SEC Form 15-12G filed by FoxWayne Enterprises Acquisition Corp.

    15-12G - FoxWayne Enterprises Acquisition Corp. (0001829999) (Filer)

    2/6/23 5:17:14 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 25-NSE filed by FoxWayne Enterprises Acquisition Corp.

    25-NSE - FoxWayne Enterprises Acquisition Corp. (0001829999) (Subject)

    1/27/23 4:38:29 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 425 filed by FoxWayne Enterprises Acquisition Corp.

    425 - FoxWayne Enterprises Acquisition Corp. (0001829999) (Subject)

    1/24/23 5:27:10 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FOXW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FOXWAYNE ENTERPRISES ACQUISITION CORP. ANNOUNCES CHANGE OF SPECIAL MEETING DATE AND INCREASE IN ITS CONTRIBUTION TO THE TRUST ACCOUNT FOR EXTENSION PROPOSAL

    NEW YORK, Nov. 29, 2022 /PRNewswire/ -- FoxWayne Enterprises Acquisition Corp. ("FoxWayne" or the "Company") (Nasdaq: "FOXW", "FOXWU", "FOXWW") announced today that its special meeting of stockholders (the "Special Meeting") originally scheduled for Wednesday, November 30, 2022, is being postponed to Tuesday December 13, 2022. At the Special Meeting, stockholders will be asked to vote on the following proposals: (1) a proposal to approve an amendment (the "Extension Amendment") to the Company's Second Amended and Restated Certificate of Incorporation to extend the date by which the Company must consummate a business combination for three months, from January 22, 2023 (the "Original Terminati

    11/29/22 5:20:00 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Live Streaming Social Entertainment Platform Powering the Creator Economy, Clover Inc., to Merge with Special Purpose Acquisition Company, FoxWayne Enterprises Acquisition Corp., to Become Public Company

    New entity poised to accelerate the development of Clover's next generation platform for live streaming with a suite of new product introductions. Clover has a growing user base of over 9 million with almost 90% of users between 18-39 years old.  Clover is targeting a launch of VR ('Virtual Reality') Dating and VR Live Streaming in Q4 2023. NEW YORK, Sept. 20, 2022 /PRNewswire/ -- Clover Inc. ("Clover" or the "Company"), a highly rated live streaming company focused on Gen Z and Millennial audiences and creators, and FoxWayne Enterprises Acquisition Corp. (NASDAQ: FOXW, FOXWW) ("FoxWayne"), a special purpose acquisition company ("SPAC"), today announced they have entered into a definitive bu

    9/20/22 8:08:00 AM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aerami Therapeutics Holdings, Inc. and FoxWayne Enterprises Acquisition Corp. Mutually Agree to Terminate Business Combination Agreement

    DURHAM, N.C. and NEW YORK, March 4, 2022 /PRNewswire/ -- Aerami Therapeutics Holdings, Inc. ("Aerami"), a biopharmaceutical company focused on developing inhaled therapies to treat severe respiratory and chronic diseases, and FoxWayne Enterprises Acquisition Corp. (NASDAQ:FOXW) ("FoxWayne"), a publicly traded special purpose acquisition company ("SPAC"), announced today that they have mutually agreed to terminate their previously announced business combination agreement, effective immediately. In light of current unfavorable market conditions, Aerami and FoxWayne believe that

    3/4/22 4:30:00 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FOXW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by FoxWayne Enterprises Acquisition Corp. (Amendment)

    SC 13G/A - FoxWayne Enterprises Acquisition Corp. (0001829999) (Subject)

    2/13/24 7:35:39 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by FoxWayne Enterprises Acquisition Corp. (Amendment)

    SC 13G/A - FoxWayne Enterprises Acquisition Corp. (0001829999) (Subject)

    2/12/24 11:00:29 AM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by FoxWayne Enterprises Acquisition Corp. (Amendment)

    SC 13G/A - FoxWayne Enterprises Acquisition Corp. (0001829999) (Subject)

    3/10/23 4:03:05 PM ET
    $FOXW
    Biotechnology: Pharmaceutical Preparations
    Health Care